By proceeding, you agree to our Terms of Use and Privacy Policy.
Zhittya (meaning Life in Ukrainian) is a biotechnology company based in Las Vegas, Nevada. Zhittya is seeking to commercialize human FGF-1, a naturally occurring growth factor. Since its discovery in the 1970s, FGF-1 has been extensively studied. Since 1998, Daniel Montano, Viktoriya Tamlenova-Montano, and Dr. Jack Jacobs have been working to bring this drug to market. Zhittya's management believes that FGF-1 has the potential to be a revolutionary new biological drug for the treatment of numerous diseases characterized by a lack of blood flow to an organ or tissue. There are over 75 human diseases resulting from a lack of blood flow or perfusion to tissues, and Zhittya has now targeted 19 of those disorders for treatment with FGF-1.
08-10 August 2023
For decades, alternative investments have been used primarily by institutional investors and endowments. However, the recent market environment has driven a growing interest in investments beyond traditional stocks and bonds. As savvy investors have
Event Ended
USA
Paid
Las Vegas